Investigational Drug Information for Saroglitazar

What is the drug development status for Saroglitazar?

Saroglitazar is an investigational drug.

There have been 20 clinical trials for Saroglitazar. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1^st 2025.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Zydus Therapeutics Inc., Zydus Discovery DMCC, and Asian Institute of Gastroenterology, India.

There are two hundred and sixty US patents protecting this investigational drug and five hundred and sixty-three international patents.

Summary for Saroglitazar

US Patents	260
International Patents	563
US Patent Applications	595
WIPO Patent Applications	206
Japanese Patent Applications	26
Clinical Trial Progress	Phase 2 (2025-12-01)
Vendors	46

Recent Clinical Trials for Saroglitazar

Title	Sponsor	Phase
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes	Zydus Therapeutics Inc.	PHASE3
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease	Zydus Therapeutics Inc.	PHASE1
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Zydus Therapeutics Inc.	PHASE3

See all Saroglitazar clinical trials

Clinical Trial Summary for Saroglitazar

Top disease conditions for Saroglitazar

Top clinical trial sponsors for Saroglitazar

See all Saroglitazar clinical trials

US Patents for Saroglitazar

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Saroglitazar		Treatment for lipodystrophy	Zydus Lifesciences Ltd
Saroglitazar		Formula comprising a hypolipidemic agent	Zydus Lifesciences Ltd
Saroglitazar		Fused triterpene compounds and uses thereof	PIRAMAL ENTERPRISES LIMITED (Mumbai, IN)
Saroglitazar		Process for the preparation of saroglitazar pharmaceutical salts	Zydus Lifesciences Ltd
Saroglitazar		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)

International Patents for Saroglitazar

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Saroglitazar	Argentina	AR097067	1989-12-31
Saroglitazar	Australia	AU2014294548	1989-12-31
Saroglitazar	Brazil	BR112015031878	1989-12-31
Saroglitazar	Canada	CA2917923	1989-12-31
Saroglitazar	China	CN105407873	1989-12-31

Saroglitazar Development Update, Patent Position and Market Projection

Last updated: September 1, 2026

Saroglitazar is a once-daily dual PPAR-alpha and PPAR-gamma agonist developed by Zydus Lifesciences. It is approved in India as saroglitazar magnesium for diabetic dyslipidemia and hypertriglyceridemia associated with type 2 diabetes. Its main value opportunity remains metabolic dysfunction-associated steatohepatitis, formerly called nonalcoholic steatohepatitis, or MASH/NASH. As of June 2024, saroglitazar had not received U.S. FDA approval and had no U.S. Orange Book listing.

The commercial outlook is mixed. Zydus has an established Indian product and manufacturing base, but the largest value driver, U.S. MASH approval, remains unproven. A successful U.S. launch could support peak global sales above $1 billion in an optimistic scenario. Failure to secure U.S. approval would leave saroglitazar primarily exposed to India and selected international markets, with a substantially lower revenue ceiling.

What is saroglitazar and how does it work?

Saroglitazar is a small-molecule agonist of PPAR-alpha and PPAR-gamma.

PPAR-alpha activation improves triglyceride and lipid metabolism. PPAR-gamma activation improves insulin sensitivity and glycemic control. The dual mechanism is intended to address dyslipidemia, insulin resistance, hepatic steatosis and inflammatory or fibrotic consequences of metabolic disease.

The active pharmaceutical ingredient is generally marketed as saroglitazar magnesium. Zydus launched Lipaglyn in India in 2013 for diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes who were inadequately controlled by statins or were statin intolerant. The company later developed applications in NASH/MASH, primary biliary cholangitis, alcoholic liver disease and other metabolic indications.

Saroglitazar differs from pioglitazone because it combines PPAR-alpha activity with PPAR-gamma activity and is positioned at a lower PPAR-gamma intensity. This profile is intended to reduce the weight gain, edema and other liabilities associated with stronger PPAR-gamma agonism, although the clinical and regulatory significance of that distinction depends on indication-specific data.

What is the current regulatory status of saroglitazar?

India

Saroglitazar is approved and commercially available in India. Lipaglyn is the principal branded product. Zydus has also marketed saroglitazar under additional brand names and has pursued line extensions and combination products.

The Indian regulatory approval established a commercial base but does not establish approval for MASH in the United States or Europe. India remains the clearest source of current saroglitazar revenue.

United States

Saroglitazar is investigational in the United States. The FDA granted Fast Track designation for saroglitazar in NASH with fibrosis in 2019, according to Zydus disclosures. Fast Track designation can facilitate interaction with the FDA and permit rolling review, but it does not indicate efficacy or approval.

Zydus conducted the EVIDENCES IV Phase 2 study in patients with NASH and type 2 diabetes. Publicly reported results indicated improvements in liver fat, liver enzymes and metabolic parameters, but the program still required evidence adequate for regulatory approval, including clinically meaningful effects on fibrosis or accepted surrogate endpoints.

Europe and other markets

Saroglitazar did not have broad European approval as of June 2024. Zydus has pursued international development and regulatory filings, but the commercial status varies by country. Regulatory success outside India depends on trial design, histologic or noninvasive endpoints, long-term safety and the evolving MASH approval standard.

What clinical trials are evaluating saroglitazar?

Program or indication	Development status as of June 2024	Strategic relevance
Diabetic dyslipidemia and hypertriglyceridemia	Approved in India	Existing commercial base
NASH/MASH with type 2 diabetes	Phase 2 development and regulatory interaction	Primary value driver
NASH/MASH without diabetes	Clinical development interest	Expands addressable population
Primary biliary cholangitis	Mid-stage development reported by Zydus	Orphan or specialty opportunity
Alcoholic liver disease	Early or exploratory development	Longer-dated option
Other metabolic and liver indications	Exploratory	Portfolio diversification

The critical development question is whether saroglitazar can demonstrate sufficient antifibrotic benefit. Improvements in alanine aminotransferase, aspartate aminotransferase, triglycerides, insulin sensitivity and hepatic fat support biological activity, but they do not automatically satisfy the FDA’s approval standard for MASH.

The competitive benchmark has strengthened. Madrigal Pharmaceuticals’ resmetirom received FDA approval in March 2024 for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, expanding the regulatory and commercial benchmark for liver-directed metabolic therapies. Novo Nordisk’s semaglutide and other incretin-based programs also compete for the same metabolic and liver-disease populations, even when their approved indications differ.

When could saroglitazar lose or gain exclusivity?

Saroglitazar’s effective exclusivity is jurisdiction-specific and depends on patents, regulatory exclusivity and any granted extensions. The basic composition-of-matter estate is older than the commercial product, which limits the likely duration of unchallenged protection in mature markets.

Zydus can extend protection through later patents covering:

• Specific salt forms, including saroglitazar magnesium
• Crystalline or polymorphic forms
• Pharmaceutical compositions
• Manufacturing processes
• Dosage regimens
• Combination therapies
• Use in NASH/MASH, dyslipidemia or other liver diseases

The commercial value of later patents depends on claim scope and validity. Method-of-use patents may deter some competitors but are generally easier to design around than a strong composition-of-matter patent. Formulation and process patents can delay competition where the product requires a particular solid form, impurity profile or manufacturing route.

No reliable single worldwide expiration date can be assigned to the entire saroglitazar estate. Patent expiration differs by family, country and claim type. The earliest core chemical protection is likely to be less important than later indication, formulation and process patents in determining launch timing.

What patents protect saroglitazar?

The protection strategy is expected to include a combination of compound, salt, formulation, process and therapeutic-use claims. Publicly available company and patent records indicate that Zydus has pursued intellectual property around saroglitazar and its pharmaceutical applications, but patent families should be reviewed individually in each jurisdiction before making an exclusivity or freedom-to-operate decision.

Patent category	Commercial purpose	Competitive vulnerability
Core compound claims	Protect the active molecule	Highest value, but earliest expiry risk
Magnesium salt claims	Protect the marketed API form	Can be challenged through alternative salts or forms
Solid-state and polymorph claims	Control physical form and stability	Depends on claim specificity and reproducibility
Formulation claims	Protect tablets, dosage strength or release profile	Often vulnerable to non-infringing formulations
Manufacturing-process claims	Increase production barriers	Competitors may develop independent routes
Method-of-use claims	Protect MASH, diabetic dyslipidemia or other uses	Subject to indication carve-outs and design-around
Combination claims	Pair saroglitazar with other metabolic agents	Narrower but useful for lifecycle management

Saroglitazar does not have an FDA Orange Book listing as of June 2024 because it is not an FDA-approved drug. Consequently, there is no U.S. Orange Book patent certification framework currently attached to an approved saroglitazar reference product.

What is the Orange Book status of saroglitazar?

Saroglitazar has no U.S. Orange Book status as an approved reference-listed drug. The implications are direct:

1. No U.S. generic can file an ANDA referencing an FDA-approved saroglitazar product.
2. A future U.S. applicant would likely require an NDA or another FDA-accepted regulatory pathway unless a qualifying reference product and approval basis become available.
3. Paragraph IV litigation cannot begin against an Orange Book-listed saroglitazar product until an approved reference product has listed patents.
4. Patent disputes could still arise under the Hatch-Waxman framework after approval or through ordinary patent litigation involving development, manufacturing or commercialization.

India presents a different legal and regulatory framework. Indian patent challenges, compulsory licensing considerations and generic substitution are not governed by the Orange Book.

Which companies are challenging saroglitazar?

No major company had publicly disclosed a late-stage, directly competing saroglitazar program as of June 2024. The competitive threat comes from alternative mechanisms and approved or advancing therapies.

Competitor or class	Company	Competitive position
Resmetirom	Madrigal Pharmaceuticals	First FDA-approved therapy for noncirrhotic MASH with moderate to advanced fibrosis
Semaglutide	Novo Nordisk	Strong metabolic and weight-loss profile; MASH development relevance
Tirzepatide	Eli Lilly	Diabetes and obesity franchise with potential liver-disease utility
Pioglitazone	Generic manufacturers	Low-cost PPAR-gamma comparator, limited by tolerability
GLP-1 receptor agonists	Multiple companies	Compete for patients with obesity, diabetes and fatty liver disease
FGF21 analogs and other liver agents	Multiple companies	Potentially stronger liver-specific efficacy in selected populations

Saroglitazar’s differentiation would require a combination of liver efficacy, lipid control, glycemic benefit, tolerability and price. Resmetirom creates a direct approved benchmark for MASH. Incretin therapies create an indirect but powerful commercial benchmark because many MASH patients also have obesity or type 2 diabetes.

How strong is the saroglitazar patent estate?

The estate has moderate strategic value but uncertain blocking power in the United States.

Its strengths are:

• Early ownership by an integrated originator
• Multiple possible lifecycle categories
• A marketed product in India
• Manufacturing experience and established API capabilities
• Potential use patents tied to a differentiated liver indication

Its weaknesses are:

• No U.S. approved product or Orange Book-listed patents
• Aging core-molecule protection
• Potentially narrow method-of-use claims
• Competition from non-infringing mechanisms
• Regulatory dependence on clinical evidence rather than patent protection alone

The strongest potential protection would come from valid claims covering the specific active form, a commercially necessary formulation or a clinically defined MASH regimen. Process patents are useful for manufacturing control but normally provide weaker market exclusion than composition claims.

What litigation and Paragraph IV risks exist?

As of June 2024, no material U.S. Paragraph IV litigation involving an FDA-approved saroglitazar product had been reported. That result follows from the absence of an FDA-approved reference product and Orange Book listing.

Future U.S. litigation risk would arise in three stages:

Pre-approval development disputes

Competitors could challenge patents covering synthesis, intermediates, salts or formulations. Zydus could also bring infringement claims against a company seeking to commercialize a competing product.

Post-approval Hatch-Waxman litigation

If saroglitazar receives U.S. approval and patents are listed, an ANDA filer could submit a Paragraph IV certification. Zydus would then have a potential 45-day period to sue, which could trigger a 30-month stay of approval, subject to statutory exceptions and court decisions.

Indication carve-out risk

If the key patent covers MASH rather than the compound itself, a generic could seek approval for unpatented indications. That strategy could reduce the practical effect of a method-of-use patent unless prescribing and substitution behavior preserve the patented market.

What manufacturing and intellectual-property barriers affect saroglitazar?

Saroglitazar is a small molecule rather than a biologic. It does not face biosimilar interchangeability risk, cold-chain complexity or cell-line manufacturing barriers associated with monoclonal antibodies and other biologics.

The principal manufacturing barriers are chemical:

• Reproducible synthesis of the API
• Control of stereochemistry and impurities
• Consistent salt formation
• Solid-state control
• Stability and dissolution performance
• Scale-up economics
• Compliance with current good manufacturing practice

Zydus has an advantage from vertical integration and experience with Indian commercial production. That advantage does not prevent competitors from developing an alternative route, particularly if the core compound is no longer strongly protected.

What is the market opportunity for saroglitazar?

The commercial opportunity divides into three markets:

1. India and other markets for dyslipidemia and metabolic disease.
2. U.S. and European MASH/MASLD markets.
3. Specialty liver indications such as primary biliary cholangitis.

MASH is the main value driver because the addressable population is large and current pharmacologic treatment remains limited. The practical treated population will be much smaller than the epidemiological population because diagnosis, fibrosis staging, payer restrictions and specialist capacity constrain adoption.

Saroglitazar revenue scenarios

The following is a scenario model, not reported company guidance.

Scenario	Regulatory outcome	Estimated peak annual global sales	Main assumptions
Downside	No U.S. approval; India-led commercialization	$100 million-$250 million	Continued Indian growth, limited international uptake
Base case	Approval in one major non-Indian market or narrower MASH label	$300 million-$700 million	Specialty adoption, moderate reimbursement, competitive pressure
Upside	U.S. MASH approval with broad metabolic positioning	$1.0 billion-$2.0 billion	Strong fibrosis data, payer access, physician adoption
High case	U.S. and European approval plus multiple liver indications	Above $2.0 billion	Durable efficacy, favorable safety and broad commercial coverage

A U.S. launch would require substantial investment in hepatology sales, diagnostic education, payer evidence and post-approval studies. Zydus could seek a regional or global commercialization partner to reduce infrastructure requirements and improve market access.

How does saroglitazar compare with resmetirom and GLP-1 drugs?

Attribute	Saroglitazar	Resmetirom	GLP-1 or dual incretin therapies
Mechanism	Dual PPAR-alpha/gamma agonist	Thyroid hormone receptor beta agonist	Incretin receptor agonism
Current U.S. approval	No	Yes, for defined MASH population	Yes for diabetes and/or obesity, depending on product
Indian commercial status	Approved	Limited relative to saroglitazar	Broad and expanding
Liver-directed positioning	Central development objective	Approved liver indication	Secondary or emerging use
Weight effect	Not a primary differentiator	Generally weight reduction or neutral-to-modest effect	Often substantial weight reduction
Lipid effect	Strong potential advantage	Liver and lipid benefits	Variable, often indirect
Generic substitution risk	Future small-molecule risk	Future small-molecule risk	Patent-protected, complex commercial landscape
Main regulatory risk	Demonstrating fibrosis benefit	Post-approval safety and effectiveness	Long-term outcome and access economics

Saroglitazar’s strongest clinical positioning would be among patients with MASH who also have hypertriglyceridemia, insulin resistance or type 2 diabetes. Its weakest position would be in patients and payers seeking substantial weight loss as the primary treatment objective.

What is the likely generic launch scenario?

A generic launch is unlikely in the United States before an FDA approval and reference-product framework exists. After approval, the timing would depend on:

• Remaining composition-of-matter protection
• Listed formulation and method-of-use patents
• Regulatory exclusivity
• Whether the product receives orphan-drug protection for a specific indication
• Paragraph IV challenges
• Court decisions and settlement terms
• Whether generic applicants pursue a full indication or a skinny label

In India, competition can arise earlier and may be more commercially significant because the product is already marketed and the legal environment differs. Brand erosion would depend on physician loyalty, price differences, insurance coverage and the number of competing saroglitazar products.

Are biosimilars a risk for saroglitazar?

No. Saroglitazar is a small molecule, so the relevant threat is generic competition rather than biosimilar competition.

The absence of biosimilar manufacturing barriers increases the importance of patent scope, formulation differentiation, regulatory exclusivity and brand positioning. Zydus’s manufacturing scale can reduce cost risk but cannot substitute for durable market exclusivity.

What licensing deals involve saroglitazar?

Zydus has retained primary control of saroglitazar development and commercialization. Publicly disclosed licensing activity has not established a major global partnership comparable to the large licensing transactions common in oncology or biologics.

The most likely partnering structure would involve:

• U.S. co-development
• Regional commercialization rights
• Milestone-based licensing tied to FDA approval
• Shared manufacturing or supply arrangements
• Specialty-liver sales infrastructure

A partner could increase the probability of commercial execution but would reduce Zydus’s retained economics. In the absence of a large disclosed transaction, valuation should not assume substantial partner-funded development.

What revenue exposure does Zydus have to saroglitazar?

Saroglitazar is strategically important to Zydus because it is one of the company’s differentiated proprietary products with an established domestic market. Reported company disclosures have not consistently separated global saroglitazar revenue from the broader India branded portfolio in a way that supports a precise standalone revenue estimate.

The key financial variables are:

• Indian prescription growth
• Price and volume expansion
• New indications
• International registrations
• U.S. trial and approval costs
• Partnering economics
• Competition from low-cost generics and other metabolic drugs

Near-term value is tied to India. Long-term valuation is tied to MASH clinical and regulatory success. Investors should treat the U.S. opportunity as an option value rather than as established revenue.

Key Takeaways

• Saroglitazar is an approved Indian small-molecule therapy for diabetic dyslipidemia and hypertriglyceridemia.
• Its main global growth opportunity is MASH/NASH, but it lacked FDA approval as of June 2024.
• The FDA granted Fast Track designation, which does not establish approval probability.
• Resmetirom has raised the evidentiary and commercial standard for MASH therapies.
• Saroglitazar has no U.S. Orange Book listing and no active U.S. Paragraph IV pathway tied to an approved reference product.
• The patent estate likely includes compound, salt, formulation, process and method-of-use families, but core protection is older than the major U.S. commercial opportunity.
• Base-case peak global sales are approximately $300 million to $700 million; a successful U.S. MASH launch could support $1 billion or more.
• Generic, rather than biosimilar, competition is the relevant long-term erosion risk.
• The principal investment catalyst is credible late-stage evidence showing clinically meaningful liver-fibrosis benefit with acceptable safety.

FAQs about saroglitazar development and commercial potential

Is saroglitazar approved for fatty liver disease in the United States?

No. As of June 2024, saroglitazar was not FDA-approved for MASH, NASH or another liver indication in the United States.

What company owns saroglitazar?

Zydus Lifesciences, through its pharmaceutical subsidiaries, is the principal developer and commercial owner associated with saroglitazar and Lipaglyn.

Can saroglitazar compete with resmetirom?

Yes, if it obtains approval for an overlapping MASH population. Its potential differentiation is the combination of liver, lipid and glycemic effects. Resmetirom has the regulatory advantage because it already has FDA approval.

Does saroglitazar cause weight gain like pioglitazone?

Saroglitazar was designed to provide PPAR-alpha and PPAR-gamma activity with a different balance from pioglitazone. Weight change, edema and other PPAR-gamma-related effects remain clinically relevant safety questions and must be assessed from controlled trial data.

What would make saroglitazar commercially successful?

The highest-value profile would be a clear MASH efficacy result, particularly fibrosis improvement, combined with favorable effects on triglycerides and glycemic control, limited weight gain, broad reimbursement and a manageable patent challenge risk.

References

1. U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

2. Zydus Lifesciences Limited. (2023). Annual report 2022-23. https://www.zyduslife.com

3. Zydus Lifesciences Limited. (2019). Saroglitazar receives U.S. FDA Fast Track designation for NASH. https://www.zyduslife.com

4. ClinicalTrials.gov. (n.d.). Study of saroglitazar magnesium in patients with nonalcoholic steatohepatitis and type 2 diabetes mellitus. U.S. National Library of Medicine. https://clinicaltrials.gov

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

6. Central Drugs Standard Control Organisation. (2013). Approval of saroglitazar magnesium for diabetic dyslipidemia and hypertriglyceridemia. Government of India. https://cdsco.gov.in